Figure 2.
Transcriptomic comparison of t(11:14) and other MM patients. (A-C) The Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age 2009 cohort and (D-F) the independent Multiple Myeloma Research Foundation cohort. (A,D) Heat map of the normalized expression of CCND1 and BCL2/BCL2L1 and BCL2/MCL1 expression ratio in the cohorts. The t(11;14) patients (indicated in pink on the first line) cluster in 2 distinct groups based on their BCL2/BCL2L1 ratio. (B,E) Normalized expression of differentially expressed genes from the apoptosis family between t(11;14) and non-t(11;14) patients. (C,F) Normalized expression ratio of BCL2/BCL2L1 between t(11;14) and non-t(11;14) patients.

Transcriptomic comparison of t(11:14) and other MM patients. (A-C) The Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age 2009 cohort and (D-F) the independent Multiple Myeloma Research Foundation cohort. (A,D) Heat map of the normalized expression of CCND1 and BCL2/BCL2L1 and BCL2/MCL1 expression ratio in the cohorts. The t(11;14) patients (indicated in pink on the first line) cluster in 2 distinct groups based on their BCL2/BCL2L1 ratio. (B,E) Normalized expression of differentially expressed genes from the apoptosis family between t(11;14) and non-t(11;14) patients. (C,F) Normalized expression ratio of BCL2/BCL2L1 between t(11;14) and non-t(11;14) patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal